ACADIA Pharmaceuticals Inc. ACAD
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 11.15% | 14.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.15% | 14.88% | |||
| Cost of Revenue | 1.37% | 8.08% | |||
| Gross Profit | 16.57% | 19.04% | |||
| SG&A Expenses | -0.66% | -6.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.17% | -0.94% | |||
| Operating Income | 89.55% | 919.67% | |||
| Income Before Tax | 73.09% | 1,067.37% | |||
| Income Tax Expenses | 79.76% | 4,252.62% | |||
| Earnings from Continuing Operations | 69.92% | 766.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 69.92% | 766.10% | |||
| EBIT | 89.55% | 919.67% | |||
| EBITDA | 83.86% | 2,625.75% | |||
| EPS Basic | 68.95% | 761.97% | |||
| Normalized Basic EPS | 72.12% | 1,059.59% | |||
| EPS Diluted | 72.22% | 800.00% | |||
| Normalized Diluted EPS | 70.54% | 1,066.67% | |||
| Average Basic Shares Outstanding | 0.55% | 0.64% | |||
| Average Diluted Shares Outstanding | 1.51% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||